Synthesis and Biological Evaluation of cis-Restrained Carbocyclic Combretastatin A-4 Analogs: Influence of the Ring Size and Saturation on Cytotoxic Properties
-
Add time:09/05/2019 Source:sciencedirect.com
ABSTRACTCombretastatin A-4 (CA-4) is a highly cytotoxic natural product and several derivatives have been prepared which underwent clinical trial. These investigations revealed that the cis-stilbene moiety of the natural product is prone to undergo cis/trans isomerization under physiological conditions, reducing the overall activity of the drug candidates. Herein, we report the preparation of cis-restrained carbocyclic analogs of CA-4. The compounds, which differ by the size and hybridization of the carbocyclic ring have been evaluated for their cytotoxic properties and their ability to inhibit tubulin polymerization. Biological data, supported by molecular docking studies, identified cyclobutenyl and cyclobutyl derivatives of the natural product as highly promising drug candidates.
We also recommend Trading Suppliers and Manufacturers of Combretastatin A-3 (cas 111394-45-7). Pls Click Website Link as below: cas 111394-45-7 suppliers
Prev:Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies
Next:Research paperDesign, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Synthesis and biological evaluation of pyrimidine bridged combretastatin derivatives as potential anticancer agents and mechanistic studies09/04/2019
- Synthesis and in vitro cytotoxicity evaluation of β-carboline-combretastatin carboxamides as apoptosis inducing agents: DNA intercalation and topoisomerase-II inhibition09/03/2019
- Review articleCombretastatins: In vitro structure-activity relationship, mode of action and current clinical status09/02/2019
- Full length articleCo-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma09/01/2019
- Review articleDevelopment of combretastatins as potent tubulin polymerization inhibitors08/31/2019
- Synthesis and characterization of a photoresponsive doxorubicin/combretastatin A4 hybrid prodrug08/30/2019
-
Health and Chemical more >
-
Related Products


